Safety, efficacy, and pharmacokinetics of SH‐1028 in EGFR T790M‐positive advanced non–small cell lung cancer patients: A dose‐escalation phase 1 study
Sign Up to like & getrecommendations! Published in 2023 at "Cancer"
DOI: 10.1002/cncr.34697
Abstract: SH‐1028 is a new third‐generation EGFR tyrosine kinase inhibitors (TKI) to benefit patients with EGFR T790M‐mutated NSCLC. Here, the authors report its clinical safety, preliminary efficacy, and pharmacokinetic (PK) profile for the first time. read more here.
Keywords: safety; safety efficacy; cancer; egfr t790m ... See more keywords
Structural pharmacological studies on EGFR T790M/C797S.
Sign Up to like & getrecommendations! Published in 2017 at "Biochemical and biophysical research communications"
DOI: 10.1016/j.bbrc.2017.04.138
Abstract: Drug-resistance is a major challenge in targeted therapy of EGFR mutated non-small cell lung cancers (NSCLCs). The third-generation irreversible inhibitors such as AZD9291, CO-1686 and WZ4002 can overcome EGFR T790M drug-resistance mutant through covalent binding… read more here.
Keywords: structural pharmacological; egfr t790m; pharmacological studies; t790m c797s ... See more keywords
Crystal structure of EGFR T790M/C797S/V948R in complex with EAI045.
Sign Up to like & getrecommendations! Published in 2018 at "Biochemical and biophysical research communications"
DOI: 10.1016/j.bbrc.2018.05.154
Abstract: Lung cancer is the leading cause of cancer deaths. Epidermal growth factor receptor (EGFR) kinase domain mutations are a common cause of non-small cell lung cancers (NSCLCs), a major subtype of lung cancers. Patients harboring… read more here.
Keywords: structure; egfr t790m; v948r complex; t790m c797s ... See more keywords
New acrylamide-substituted quinazoline derivatives with enhanced potency for the treatment of EGFR T790M-mutant non-small-cell lung cancers.
Sign Up to like & getrecommendations! Published in 2018 at "Bioorganic chemistry"
DOI: 10.1016/j.bioorg.2018.01.035
Abstract: A new class of acrylamide-substituted quinazoline derivatives with enhanced inhibitory activity against mutant EGFR T790M enzyme were synthesized. Among them, compound 10b displayed the strongest inhibitory potency to block the phosphorylation of the EGFR T790M… read more here.
Keywords: egfr; compound 10b; egfr t790m; t790m ... See more keywords
EGFR T790M ctDNA testing platforms and their role as companion diagnostics: Correlation with clinical outcomes to EGFR-TKIs.
Sign Up to like & getrecommendations! Published in 2017 at "Cancer letters"
DOI: 10.1016/j.canlet.2017.06.008
Abstract: Somatic mutation in the epidermal growth factor receptor (EGFR) predict clinical response to EGFR tyrosine kinase inhibitors in non-small cell lung cancer (NSCLC) and is a promising target for personalised medicine. EGFR mutations have prognostic… read more here.
Keywords: egfr; egfr t790m; companion diagnostics; tyrosine kinase ... See more keywords
Primary and acquired EGFR T790M-mutant NSCLC patients identified by routine mutation testing show different characteristics but may both respond to osimertinib treatment.
Sign Up to like & getrecommendations! Published in 2018 at "Cancer letters"
DOI: 10.1016/j.canlet.2018.03.005
Abstract: Primary EGFR T790M mutation is occasionally identified by routine mutation testing in tyrosine kinase inhibitor (TKI)-naive patients with non-small cell lung cancer (NSCLC). We herein aimed to compare the characteristics of primary and acquired T790M… read more here.
Keywords: egfr t790m; acquired t790m; t790m mutant; primary acquired ... See more keywords
Cost-effectiveness of Osimertinib vs Docetaxel-Bevacizumab in Third-Line Treatment in EGFR T790M Resistance Mutation Advanced Non-Small Cell Lung Cancer in China.
Sign Up to like & getrecommendations! Published in 2020 at "Clinical therapeutics"
DOI: 10.1016/j.clinthera.2020.08.018
Abstract: PURPOSE This study aimed to evaluate the cost-effectiveness of osimertinib vs docetaxel and bevacizumab in third-line treatment in EGFR T790M resistance mutation advanced non-small cell lung cancer in China from the perspective of the health… read more here.
Keywords: per qaly; egfr t790m; docetaxel bevacizumab; model ... See more keywords
An evaluation of aumolertinib for the treatment of EGFR T790M mutation-positive non-small cell lung cancer
Sign Up to like & getrecommendations! Published in 2022 at "Expert Opinion on Pharmacotherapy"
DOI: 10.1080/14656566.2022.2050213
Abstract: ABSTRACT Introduction Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) can significantly improve patient prognosis when used on patients with EGFR-mutant non-small cell lung cancer (NSCLC), but those patients often develop acquired resistance after 9–14… read more here.
Keywords: treatment; egfr t790m; t790m mutation;
Clinical outcomes and safety of osimertinib plus anlotinib for patients with previously treated EGFR T790M-positive NSCLC: A retrospective study.
Sign Up to like & getrecommendations! Published in 2022 at "Journal of clinical pharmacy and therapeutics"
DOI: 10.1111/jcpt.13591
Abstract: WHAT IS KNOWN AND OBJECTIVE Although osimertinib achieved convincing efficacy for patients with EGFR T790M-positive non-small-cell lung cancer (NSCLC) as second-line treatment in the AURA3 clinical trials, patients developed drug resistance ultimately. Therefore, the present… read more here.
Keywords: t790m positive; plus anlotinib; study; safety ... See more keywords
Abstract 780: Digital PCR-based EGFR T790M mutation detection from human blood samples collected in PAXgene Blood ccfDNA Tubes
Sign Up to like & getrecommendations! Published in 2023 at "Cancer Research"
DOI: 10.1158/1538-7445.am2023-780
Abstract: Introduction: Circulating cell-free DNA (ccfDNA) is used as an analyte in liquid biopsy-based cancer research with promising applications in the fields of cancer screening, therapeutic decision making and monitoring and minimal residual disease control. However,… read more here.
Keywords: blood ccfdna; ccfdna; blood; mutation ... See more keywords
Treatment of Leptomeningeal Metastases in a Patient with Non-Small Cell Lung Cancer Harboring EGFR T790M Mutation
Sign Up to like & getrecommendations! Published in 2017 at "Case Reports in Oncology"
DOI: 10.1159/000480452
Abstract: Background: Leptomeningeal metastasis (LM) is an uncommon complication in patients with solid tumors, associated with poor survival. However, LM appears to be more frequent in lung cancer patients with EGFR mutations, posing a unique clinical… read more here.
Keywords: egfr t790m; lung cancer; t790m mutation; harboring egfr ... See more keywords